Published on 13 Nov 2023 on GuruFocus.com via Yahoo Finance

ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments

ALX Oncology Holdings Inc (NASDAQ:ALXO) announced positive interim Phase 2 clinical trial results and completed a public offering generating $63.2 million.Leadership realignment to focus on the development of the platform asset evorpacept.Reported a net loss of $51.0 million for Q3 2023, with R&D expenses increasing due to the advancement of evorpacept.ALX Oncology believes its financial resources are sufficient to fund operations into early 2026.

Warning! GuruFocus has detected 2 Warning Signs with ALXO.

On November 13, 2023, ALX Oncology Holdings Inc (NASDAQ:ALXO) released its 8-K filing, announcing its financial results for the third quarter ended September 30, 2023, and providing a corporate update. The company, which is developing therapies that block the CD47 immune checkpoint pathway, highlighted several key achievements and developments during the quarter.